Gorbalenya, A. E. et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).

Article  CAS  Google Scholar 

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https://covid19.who.int/. (2022).

Grasselli, G. et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 323, 1574 (2020).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Coutard, B. et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 176, 104742 (2020).

Guy, B. et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22, 3563–3574 (2004).

PubMed  Article  CAS  Google Scholar 

Smith, N. et al. Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nat. Immunol. 22, 1428–1439 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Pisanic, N. et al. COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. J. Clin. Microbiol. 59, e02204-20 (2020).

Ye, X. et al. Serum IgG anti-SARS-CoV-2 binding antibody level is strongly associated with IgA and functional antibody levels in adults infected with SARS-CoV-2. Front. Immunol. 12, 693462 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Zervou, F. N. et al. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. J. Med. Virol. https://doi.org/10.1002/jmv.2705 (2021).

Legros, V. et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell. Mol. Immunol. 18, 318–327 (2021).

Hartog, G. den et al. Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab172 (2021).

Havervall, S. et al. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. PLoS ONE 17, e0262169 (2022).

Al-Mughales, J. A., Al-Mughales, T. J. & Saadah, O. I. Monitoring specific IgM and IgG production among severe COVID-19 patients using qualitative and quantitative immunodiagnostic assays: a retrospective cohort study. Front. Immunol. 12, 705441 (2021).

Wu, J. et al. Occurrence of COVID-19 symptoms during SARS-CoV-2 infection defines waning of humoral immunity. Front. Immunol. 12, 722027 (2021).

Sasson, J. M. et al. Diverse humoral immune responses in younger and older adult COVID-19 patients. mBio 12, e0122921 (2021).

Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024–1042.e21 (2020).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Tang, G. et al. The dynamic immunological parameter landscape in coronavirus disease 2019 patients with different outcomes. Front. Immunol. 12, 697622 (2021).

Kopanja, S. et al. Characterization of the antibody response to SARS-CoV-2 in a mildly affected pediatric population. Pediatr. Allergy. Immunol. 33, e13737 (2022).

Konik, M. et al. Long-term SARS-CoV-2 specific immunity is affected by the severity of initial COVID-19 and patient age. J. Clin. Med. 10, 4606 (2021).

Patel, S. K., Velkoska, E. & Burrell, L. M. Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? Clin. Exp. Pharmacol. Physiol. 40, 551–559 (2013).

PubMed  Article  CAS  Google Scholar 

Jacobsen, H. & Klein, S. L. Sex differences in immunity to viral infections. Front. Immunol. 12, 720952 (2021).

Weisberg, S. P. et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 22, 25–31 (2021).

PubMed  Article  Google Scholar 

Singh, A. K. et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis. Diabetes, Obes. Metab. 22, 1915–1924 (2020).

Article  CAS  Google Scholar 

Shaw, A. C., Joshi, S., Greenwood, H., Panda, A. & Lord, J. M. Aging of the innate immune system. Curr. Opin. Immunol. 22, 507–513 (2010).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576–590 (2018).

PubMed  Article  CAS  Google Scholar 

Carsetti, R. et al. The immune system of children: the key to understanding SARS-CoV-2 susceptibility? Lancet Child Adolesc. Health 4, 414 (2020).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Imai, K. et al. Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities. Int J. Infect. Dis. 111, 68–75 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Sandberg, J. T. et al. SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation. Clin. Transl. Immunol. 10, e1306 (2021).

Kurano, M. et al. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: the IgA and IgG titers increased earlier than the IgM titers. Int. Immunopharmacol. 103, 108491 (2022).

Shi, D. et al. Dynamic characteristic analysis of antibodies in patients with COVID-19: a 13-month study. Front. Immunol. 12, 708184 (2021).

Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2021).

Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2020).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Ravichandran, S. et al. Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures. Sci. Adv. 7, eabi6533 (2021).

Slezak, J. et al. Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients. Clin. Microbiol. Infect. 27, 1860.e7 (2021).

Article  CAS  Google Scholar 

Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K. & Ethelberg, S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet 397, 1204 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Isa, M. B. et al. Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals. Clin. Diagn. Lab Immunol. 9, 693–697 (2002).

PubMed  PubMed Central  CAS  Google Scholar 

Cervia, C. et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J. Allergy Clin. Immunol. 147, 545–557.e9 (2021).

PubMed  Article  CAS  Google Scholar 

Zhang, Z. et al. The potential role of an aberrant mucosal immune response to SARS-CoV-2 in the pathogenesis of IgA nephropathy. Pathogens 10, 881 (2021).

Fuentes-Villalobos, F. et al. Sustained antibody-dependent NK cell functions in mild COVID-19 outpatients during convalescence. Front. Immunol. 13, 796481 (2022).

Noh, J. Y. et al. Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: a prospective cohort study. J. Infect. Dis. https://doi.org/10.1093/INFDIS/JIAC050 (2022).

H, A. et al. Persisting salivary IgG against SARS-CoV-2 at 9 months after mild COVID-19: a complementary approach to population surveys. J. Infect. Dis. 224, 407–414 (2021).

Scheiblauer, H. et al. Antibody response to SARS-CoV-2 for more than one year—kinetics and persistence of detection are predominantly determined by avidity progression and test design. J. Clin. Virol. 146, 105052 (2022).

PubMed  Article  CAS  Google Scholar 

Suthar, M. S. et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep. Med. 1, 100040 (2020).

Chen, Y. et al. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog. 16, e1008796 (2020).

Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52, 971 (2020).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Cavacini, L. A., Kuhrt, D., Duval, M., Mayer, K. & Posner, M. R. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals. AIDS Res. Hum. Retroviruses 19, 785–792 (2003).

PubMed  Article  CAS  Google Scholar 

Frasca, D. et al. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season. Immun. Ageing 10, 14 (2013).

Lamers, M. M. et al. SARS-CoV-2 productively infects human gut enterocytes. Science 369, 50–54 (2020).

PubMed  Article  CAS  Google Scholar 

Woudenberg, T. et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. EBioMedicine 70, 103495 (2021).

Ortega, N. et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat. Commun. 12, 4740 (2021).

Greenbaum, U. et al. High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients. Front. Immunol. 12, 675679 (2021).

Dugas, M. et al. Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19. J. Clin. Virol. 139, 104847 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Dugas, M. et al. Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1). Int. J. Infect. Dis. 105, 304–306 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Sermet-Gaudelus, I. et al. Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020. Euro Surveill. 26, 2001782 (2021).

Ringlander, J. et al. Incidence and severity of Covid-19 in patients with and without previously verified infections with common cold coronaviruses. J. Infect. Dis. 223, 1831–1832 (2021).

PubMed  Article  CAS  Google Scholar 

Miyara, M. et al. Pre-COVID-19 immunity to common cold human coronaviruses induces a recall-type IgG Response to SARS-CoV-2 antigens without cross-neutralisation. Front. Immunol. 13, 790334 (2022).

Tamminen, K., Salminen, M. & Blazevic, V. Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults. Clin. Immunol. 229, 108782 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Dijkman, R. et al. Human coronavirus NL63 and 229E seroconversion in children. J. Clin. Microbiol. 46, 2368–2373 (2008).

PubMed  PubMed Central  Article  Google Scholar 

Friedman, N. et al. Human coronavirus infections in israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1. Viruses 10, 515 (2018).

PubMed Central  Article  Google Scholar 

Castagnoli, R. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 174, 882–889 (2020).

PubMed  Article  Google Scholar 

Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implicat